Stock News Update: Atossa Therapeutics (NASDAQ:ATOS)

Atossa Therapeutics (NASDAQ:ATOS) spotted trading -78.76% off 52-week high price. On the other end, the stock has been noted 31.93% away from the low price over the last 52-weeks. The stock changed 1.29% to recent value of $1.57. The stock transacted 72265 shares during most recent day however it has an average volume of 105.95K shares. The company has 9.13M of outstanding shares and 9.08M shares were floated in the market.

On Jan. 6, 2020, Atossa Therapeutics (NASDAQ:ATOS) a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions,  disclosed that its corporate name change from Atossa Genetics Inc. to Atossa Therapeutics became effective at 12:01 a.m. ET , January 6, 2020. The Company’s common stock will continue to trade on the NasdaqCM exchange under the ticker symbol ATOS.

Over the last several years, we have transitioned the Company’s focus on developing therapies to treat breast cancer, breast density and other breast conditions, said Steve Quay, Ph.D., M.D., president and CEO of Atossa. Changing our name to Atossa Therapeutics more clearly reflects our focus on developing therapies and continues to honor Princess Atossa, the great queen of the Achaemenid Empire, who reigned in the fifth century BCE and who is the earliest recorded woman with breast cancer. She is featured in the The Emperor of All Maladies: A Biography of Cancer, the Pulitzer Prize-winning book by Siddhartha Mukherjee on the history of cancer.

About Atossa Therapeutics

Atossa Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.

Its earnings per share (EPS) expected to touch remained 49.80% for this year.

According to the most recent quarter its current ratio was 10.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of 0.97% from the mean of 20 days, 4.99% from mean of 50 days SMA and performed -25.94% from mean of 200 days price. Company’s performance for the week was -1.26%, 10.06% for month.

Leave a Reply

Your email address will not be published. Required fields are marked *